Fibrin clot properties in women heterozygous for factor v Leiden mutation: Effects of oral contraceptives

Thrombosis Research

Volumn 130, Issue 4, 2012, Pages

  Krzek, Marzena ^a   Ciesla Dul, Mariola ^a   Zabczyk, Michal ^a   Undas, Anetta ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

factor V Leiden; fibrinolysis; lysis time; oral contraception; permeability

Indexed keywords

ALTEPLASE; BLOOD CLOTTING FACTOR 5 LEIDEN; D DIMER; FIBRIN; FIBRINOGEN; ORAL CONTRACEPTIVE AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; ARTICLE; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FAMILY HISTORY; FEMALE; FIBRIN CLOT; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HETEROZYGOSITY; HUMAN; ORAL CONTRACEPTION; PRIORITY JOURNAL; THROMBOCYTE COUNT; VENOUS THROMBOEMBOLISM;

ADULT; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; FACTOR V; FEMALE; FIBRIN; FIBRIN CLOT LYSIS TIME; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HETEROZYGOTE; HUMANS; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84866263188     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.08.302     Document Type: Article

References (26)

1. O. Lidegaard, B. Edstom, and S. Kreiner Oral contraceptives and venous thromboembolism: a five-year national case-control study Contraception 16 2002 187 196
2. M.E. Meltzer, T. Lisman, C.J.M. Doggen, P.G. De Groot, and F.R. Rosendaal Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis PLoS Med 5 2008 0751 0758
3. P. Anqchisuksiri Venous thromboembolism in Asia -an unrecognised and under-treated problem? Thromb Hemost 106 2011 585 590
4. K. Segers, B. Dahlback, and G.A.F. Nicolaes Coagulation factor V and thrombophilia: Background and mechanisms Thromb Hemost 98 2007 530 542
5. M. Nesheim Thrombin and fibrinolysis Chest 124 SV 2003 33 39
6. J.L. Kujovich, and V. Factor Leiden thrombophilia Genet Med 13 2011 1 16
7. A. Undas, B. Brzezinska-Kolarz, T. Orfeo, K. Brummel-Ziedins, J. Musial, and A. Szczeklik Coagulation at the site of microvascular injury in healthy and coumadin-treated subjects heterogenous for factor V Leiden mutation Thromb Haemost 98 2007 1024 1030
8. Z. Koncz, Z. Bagoly, G. Haramura, Z.A. Mezei, and L. Muszbek Thrombomodulin-dependent effect of factor V Leiden mutation on factor XIII activation Thromb Res 129 2012 508 513
9. L.A. Norris, and J. Bonnar Haemostatic changes and the oral contraceptive pill Baillieres Clin Obstet Gynaecol 11 1997 545 564
10. V. Gartner, M. Weber, and S. Eichinger The emotional impact of genetic testing and aspects of counseling prior to prescription of oral contraceptives Contraception 78 2008 392 398
11. J.M. Kemmeren, A. Algra, J.C.M. Meijers, B.N. Bouma, and D.E. Grobbee Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation Blood Coagul Fibrinolysis 13 2002 373 381
12. J. Rosing, and G. Tans Effects of oral contraceptives on hemostasis and thrombosis Am J Obstet Gynecol 180 1999 375 382
13. J.P. Collet, Y. Allali, C. Lesty, M.L. Tanguy, J. Silvain, and A. Ankri Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis Arterioscler Thromb Vasc Biol 26 2006 2567 2573
14. A. Undas, P. Podolec, K. Zawilska, M. Pieculewicz, I. Jedliński, and E. Stepień Altered fibrin clot structure/function as a novel risk factor for cryptogenic ischemic stroke Stroke 40 2009 1499 1501
15. A. Undas, and R.A.S. Ariens Fibrin clot structure and function: A role in the pathophysiology of arterial and venous thromboembolic diseases Arterioscler Thromb Vasc Biol 31 2011 e88 e99
16. A. Undas, K. Zawilska, and M. Ciesla-Dul Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives Blood 114 2009 4272 4278
17. M.E. Meltzer, T. Lisman, P.G. De Groot, J.C.M. Meijers, S. Le Cessie, and C.J.M. Doggen Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1 Blood 116 2010 113 121
18. J. Corral, V. Roldán, and V. Vicente Deep venous thrombosis or pulmonary embolism and factor V Leiden: Enigma or paradox Haematologica 95 2010 863 866
19. L. Bajzar, M. Kalafatis, P. Simioni, and P.B. Tracy An antifibrinolytic mechanism describing the prothrombotic effect associated with Factor V Leiden J Biol Chem 271 1996 22949 22952
20. A.C. Parker, L.V. Mundada, A.H. Schmaier, and W.P. Fay Factor V Leiden inhibits fibrinolysis in vivo Circulation 110 2004 3594 3598
21. J.C.M. Meijers, S. Middeldorp, W. Tekelenburg, G. Tans, M.H. Prins, and J. Rosing Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis. A randomized cross-over study of two low-dose oral contraceptives Thromb Hemost 84 2000 9 14
22. A. Undas, K. Szuldrzynski, E. Stepien, J. Zalewski, J. Godlewski, and W. Tracz Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: Effects of inflammation and oxidative stress Atherosclerosis 196 2008 551 557
23. T. Lisman, F.W.G. Leebeek, L.O. Mosnier, B.N. Bouma, J.C.M. Meijers, and H.L.A. Janssen Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis Gastroenterology 121 2001 131 139
24. A. Undas, E. Wypasek, B. Kapelak, and J. Sadowski Shorter preoperative fibrin clot lysis time predisposes to higher chest tube drainage in patients undergoing elective coronary artery bypass grafting surgery Blood Coagul Fibrinolysis 21 2010 380 381
25. A. Undas Acquired dysfibrinogemia in atherosclerotic vascular disease Pol Arch Med Wew 121 2011 310 319
26. P. Quehenberger, U. Loner, S. Kapiotis, S. Handler, B. Schnerider, and J. Huber Effects of third generation oral contraceptives containing newly developed progestagens on fibrinolytic parameters Fibrinolysis Proteol 11 1997 97 101